Alembic Pharmaceuticals Limited
Symboli: APLLTD.NS
NSE
1003.8
INRMarkkinahinta tänään
33.4305
P/E-suhde
1.2335
PEG-suhde
197.31B
MRK Cap
- 0.01%
DIV Tuotto
Alembic Pharmaceuticals Limited (APLLTD-NS) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 4739.2 | 921.2 | 610.9 | 2850.3 | |||||||||||||
balance-sheet.row.short-term-investments | 4804.2 | 166.4 | 316.2 | 1869.7 | |||||||||||||
balance-sheet.row.net-receivables | 22766.1 | 11291.1 | 11900.1 | 8067.3 | |||||||||||||
balance-sheet.row.inventory | 30145.1 | 14752.7 | 16097 | 14861.5 | |||||||||||||
balance-sheet.row.other-current-assets | 5023.9 | 2135.2 | -0.1 | -0.1 | |||||||||||||
balance-sheet.row.total-current-assets | 62674.3 | 29100.2 | 28607.9 | 25779 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 60805.5 | 29997.3 | 39472.6 | 36480.3 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 172.2 | 0 | 1548.2 | 3229.5 | |||||||||||||
balance-sheet.row.long-term-investments | 1769.2 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.tax-assets | 2467.1 | 1230.1 | 58.8 | 1108 | |||||||||||||
balance-sheet.row.other-non-current-assets | -1507.4 | 537.4 | 348.8 | -0.1 | |||||||||||||
balance-sheet.row.total-non-current-assets | 63706.6 | 32728.1 | 42612.4 | 41310.8 | |||||||||||||
balance-sheet.row.other-assets | 0.1 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 126381 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.account-payables | 14417.6 | 6798.1 | 7063.9 | 6687.7 | |||||||||||||
balance-sheet.row.short-term-debt | 14541.5 | 6527.9 | 6449.7 | 3121.8 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 21.5 | |||||||||||||
balance-sheet.row.long-term-debt-total | 1366.4 | 692.3 | 721.4 | 2714.3 | |||||||||||||
Deferred Revenue Non Current | -831.4 | -831.4 | -1976.9 | 855.2 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 831.4 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 1623.4 | 855.4 | -0.1 | 0.2 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3507.8 | 1754.3 | 1679.5 | 3611.7 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 1705.4 | 861.5 | 871.2 | 838.2 | |||||||||||||
balance-sheet.row.total-liab | 37976.2 | 18123.6 | 18844.8 | 16420.1 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 786.2 | 393.1 | 393.1 | 393.1 | |||||||||||||
balance-sheet.row.retained-earnings | 35684.4 | 35684.4 | 25543.9 | 24241 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 133047.2 | 335.4 | 18808.8 | 18513.8 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 7291.8 | 7291.8 | 7629.7 | 8128.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 176809.6 | 43704.7 | 52375.5 | 51276.1 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 214785.8 | 61828.3 | 71220.3 | 67089.8 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | -606.4 | |||||||||||||
balance-sheet.row.total-equity | 176809.6 | 43704.7 | 52375.5 | 50669.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 214785.8 | - | - | - | |||||||||||||
Total Investments | 6407 | 963.3 | 1184 | 493.1 | |||||||||||||
balance-sheet.row.total-debt | 15907.9 | 7220.2 | 7171.1 | 5836.1 | |||||||||||||
balance-sheet.row.net-debt | 15972.9 | 6465.4 | 6560.2 | 4855.5 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 5902.1 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.change-in-working-capital | 0 | -575.6 | -3673.4 | 2395.4 | |||||||||||||
cash-flows.row.account-receivables | 0 | -2228.8 | -4696.2 | 5109.3 | |||||||||||||
cash-flows.row.inventory | 0 | 1344.4 | -1235.5 | -2986.2 | |||||||||||||
cash-flows.row.account-payables | 0 | -281.7 | 366.7 | 452.7 | |||||||||||||
cash-flows.row.other-working-capital | 0 | 590.5 | 1891.6 | -180.4 | |||||||||||||
cash-flows.row.other-non-cash-items | -5902.1 | 1514.9 | 128 | -3277.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 5546.2 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 18.7 | 46.1 | -4.6 | |||||||||||||
cash-flows.row.purchases-of-investments | 0 | -70 | -1392.9 | -1861 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | -18.7 | 1869.7 | 1861 | |||||||||||||
cash-flows.row.other-investing-activites | 0 | 28.2 | 13.8 | -1788.4 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -4475.9 | -3719.7 | -8388.1 | |||||||||||||
cash-flows.row.debt-repayment | 0 | -2000 | -3000 | -3792.7 | |||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 7340.8 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | -1965.6 | -2751.9 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 0 | 1346 | 3578.4 | -9522.4 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -2619.6 | -2173.5 | -5974.3 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | -9.3 | |||||||||||||
cash-flows.row.net-change-in-cash | 5546.2 | 143.9 | -369.7 | 262.2 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 7314 | 754.8 | 610.9 | 980.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1767.8 | 610.9 | 980.6 | 718.4 | |||||||||||||
cash-flows.row.operating-cash-flow | 5546.2 | 7239.5 | 5523.5 | 14633.8 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | -4434.1 | -4256.4 | -6595.1 | |||||||||||||
cash-flows.row.free-cash-flow | 5546.2 | 2805.4 | 1267.1 | 8038.7 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 61181 | 56526.2 | 52317.9 | 52762.2 | |||||||||||||
income-statement-row.row.cost-of-revenue | 17682.1 | 17088.2 | 17231.9 | 15212.7 | |||||||||||||
income-statement-row.row.gross-profit | 43498.9 | 39438 | 35086 | 37549.5 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 4785.4 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.operating-expenses | 37416.9 | 35108.9 | 29160 | 24581.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 55099 | 52197.1 | 46391.9 | 39793.8 | |||||||||||||
income-statement-row.row.interest-income | 0 | 3.3 | 17.3 | 15.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 255.9 | 27.4 | 1.3 | 2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -479.9 | -831.8 | 379.3 | 1029.8 | |||||||||||||
income-statement-row.row.interest-expense | 596.2 | 501.7 | 177.3 | 160.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 2773.1 | 2754.3 | 2867.8 | 1834.7 | |||||||||||||
income-statement-row.row.ebitda-caps | 9020.8 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | 6131.3 | 4377.8 | 5874.7 | 12968.4 | |||||||||||||
income-statement-row.row.income-before-tax | 5651.5 | 3545.9 | 6201.1 | 13680.8 | |||||||||||||
income-statement-row.row.income-tax-expense | -250.6 | 126.1 | 1044.6 | 2533.2 | |||||||||||||
income-statement-row.row.net-income | 5902.1 | 3419.9 | 5209.4 | 11465 |
Usein kysytty kysymys
Mikä on Alembic Pharmaceuticals Limited (APLLTD.NS) taseen loppusumma?
Alembic Pharmaceuticals Limited (APLLTD.NS) kokonaisvarat ovat 61828300000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 32255000000.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.711.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on 28.216.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.096.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.100.
Mikä on Alembic Pharmaceuticals Limited (APLLTD.NS) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 3419900000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 7220200000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 35108900000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat -1478000000.000.